Loading...
XHKG
3613
Market cap926mUSD
Apr 09, Last price  
8.59HKD
1D
2.38%
1Q
7.24%
Jan 2017
-18.03%
IPO
8.05%
Name

Beijing Tong Ren Tang Chinese Medicine Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
13.31
P/S
4.72
EPS
0.65
Div Yield, %
7.68%
Shrs. gr., 5y
—
Rev. gr., 5y
0.15%
Revenues
1.52b
-11.91%
333,039,000613,963,000761,051,000970,477,0001,084,280,0001,265,994,0001,513,873,0001,432,632,0001,315,346,0001,556,158,0001,731,095,0001,524,945,000
Net income
540m
-16.33%
155,935,000220,001,000287,124,000354,249,000420,315,000489,967,000580,720,000556,118,000542,456,000607,838,000645,875,000540,393,000
CFO
461m
-15.82%
185,096,000142,528,000244,734,000353,576,000467,721,000469,144,000577,684,000551,010,000116,054,000777,170,000547,444,000460,831,000
Dividend
Jun 12, 20240.33 HKD/sh
Earnings
Jun 06, 2025

Profile

Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. The company operates through three segments: Hong Kong, Mainland China, and Overseas. It also offers Chinese medical consultation and treatment services. The company operates 23 retail outlets in Hong Kong and 46 retail outlets in other countries and regions in Asia, Oceania, North America, and Europe. It markets its products under the Tong Ren Tang brand. The company was founded in 1669 and is based in Wan Chai, Hong Kong.
URL
https://cm.tongrentang.com/
IPO date
May 07, 2013
Employees
789
Domiciled in
HK
Incorporated in
HK

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,524,945
-11.91%
1,731,095
11.24%
Cost of revenue
900,200
930,335
Unusual Expense (Income)
NOPBT
624,745
800,760
NOPBT Margin
40.97%
46.26%
Operating Taxes
97,203
134,669
Tax Rate
15.56%
16.82%
NOPAT
527,542
666,091
Net income
540,393
-16.33%
645,875
6.26%
Dividends
(276,243)
(443,663)
Dividend yield
2.71%
4.62%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
56,420
42,348
Long-term debt
206,874
163,264
Deferred revenue
333
Other long-term liabilities
(333)
Net debt
(2,175,200)
(1,847,968)
Cash flow
Cash from operating activities
460,831
547,444
CAPEX
(21,866)
(38,509)
Cash from investing activities
(1,078,521)
335,412
Cash from financing activities
(372,181)
(535,416)
FCF
338,464
451,332
Balance
Cash
2,378,693
2,243,963
Long term investments
59,801
(190,383)
Excess cash
2,362,247
1,967,025
Stockholders' equity
4,070,108
3,779,859
Invested Capital
1,790,256
1,734,039
ROIC
29.94%
35.77%
ROCE
15.01%
21.59%
EV
Common stock shares outstanding
837,100
837,100
Price
12.16
6.11%
11.46
-14.61%
Market cap
10,179,136
6.11%
9,593,166
-14.61%
EV
8,158,113
7,907,447
EBITDA
707,259
876,230
EV/EBITDA
11.53
9.02
Interest
5,978
4,661
Interest/NOPBT
0.96%
0.58%